HER2+ breast cancer cells as well as xenografts derived from them are able to induce autophagy upon Lapatinib treatment, and this correlates with inhibition of HER2 phosphorylation, disruption of the HER/Beclin 1 complex and induction of autophagy. Here, ERBB2 is linked to breast carcinoma.